Cassava Sciences develops drugs for neurodegenerative diseases and has completed a Phase 2b clinical trial for its lead therapeutic product candidate, simufilam. The company also has an investigational diagnostic product candidate, SavaDx, which detects Alzheimer's disease through a blood-based biomarker/diagnostic. Formerly known as Pain Therapeutics, Cassava Sciences was founded in 1998 and is headquartered in Austin, Texas.